Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1983-07-12
1985-10-15
Rosen, Sam
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 76, 514 77, 514 78, A61K 3700, A61K 31685
Patent
active
045474907
ABSTRACT:
A composition of matter which comprises a synthetic whole blood useful as a substitute for whole natural blood and a method of making the same are disclosed. The method of manufacture yields a composition of matter comprised of a two phase coacervate system. The claimed system successfully duplicates the two phase heterogeneous physicochemical system of naturally occurring whole blood. Also, disclosed is a phase of the claimed method of manufacture which produces a composition of matter, useful as a substitute for hematocrit. Also disclosed is an embodiment employing a hemoglobin component selected from stroma free hemoglobin, synthetic liposomes containing stroma free hemoglobin, microencapsulated stroma free hemoglobin, microspheres of albumin containing stroma free hemoglobin, or emulsified droplets of the coacervate phase containing stroma free hemoglobin. It is preferred that the size of the hemoglobin component particles and the globules of the synthetic hematocrit and the synthetic whole blood range in size from 0.1 to 10 microns.
REFERENCES:
patent: 2591133 (1952-04-01), Campbell et al.
patent: 4001401 (1977-04-01), Bonsen et al.
patent: 4002739 (1977-01-01), Turner et al.
patent: 4133874 (1979-01-01), Miller et al.
Selkurt-Physiology-2nd Edit. (Little-Brown), (1966), p. 218.
Guyton-Basic Human Physiology (Saunders), (1971), p. 157.
Watanabe et al.-Chem. Abst., vol. 81 (1974), p. 16715v.
Campbell et al.-Chem. Abst., vol. 46 (1952), p. 6797a.
Ricketts-Chem. Abst., vol. 46 (1952), p. 1215f.
Kaplan et al.-Chem. Abst., vol. 83 (1975), p. 53540w.
Vinograd-Finkel et al.-Chem. Abst., vol. 77 (1972), p. 86318j.
Chem Abst.-8th Coll. Index, Benzimidazolin-By, pp. 5070, 5071, 5144 and 5145 (1972) and 5145s, 5146s and 5076s.
A. Veis and C. Aranyi, "Phase Separation in Polyelectrolyte Systems, I. Complex Coacervates of Gelatin", Journal of Physical Chemistry, vol. 64 (1960), pp. 203-210.
Merck Manual, 14th Ed., (Rahway, N.J.: Merck & Co., Inc., 1982).
Arthur Osol, Ed., Remington's Pharmaceutical Sciences (Easton, Pa.: Mack Publishing Co., 1975), p. 315.
J. McMullen et al., "Pectin-Gelatin Complex Coacervates", Journal of Pharmaceutical Science, vol. 71, No. 6 (Jun., 1982), pp. 628-633.
H. H. deJong in Colloid Science by H. R. Kruyt, vol. ii (Elsevoir, Amsterdam, 1949).
Gessner G. Hawley, Ed., The Condensed Chemical Dictionary, 9th Ed., (New York: Van Nostrand Reinhold Company, 1977), p. 213.
"Blood", Van Nostrand's Scientific Encyclopedia, 1968, pp. 214-215.
Documenta Geigy, (Basle, Switzerland: J. R. Geigy, 1956).
Geigy Scientific Tables, 8th Ed. (Basle, Switzerland: Ciba-Geigy, Ltd., 1982).
Department of Defense, Document No. 84-R-0033, p. 7.
Ostra, Liposomes, (New York: Marcelle-Deeker, 1980).
R. Goodman et al., "Cytotoxicity of a Perfluorocarbon Blood Substitute to Macrophages in Vitro", Science, vol. 220, (May, 1983), pp. 965-967.
P. Lundsgaard-Hansen, M.D. and B. Tschirren, M.D., "Modified Fluid Gelatin as a Plasma Substitute", Blood Substitutes and Plasma Expanders, (New York: Alan R. Liss, 1978), p. 227.
Merck Manual, 10 Ed. (Rahway, N.J.: Merck & Co., Inc., 1983).
Ashwood-Smith, M. S., "Polyvinyl-Pyrolidone Solutions Used in Plasma Expander Potential Carcinogens"; Lancet 1 (1971), p. 1304.
Towers, R. P., "Lymph Node Changes Due to Polyvinyl-Pyrolidone"; Journal of Clinical Pathology 10, (1975-1977), p. 1957.
DeVenute, Frank and Zegna, Angelo, "Blood Exchanger with Pyridoxilated and Polymerized Hemoglobin Solution", Surgery, Gynecology and Obstetrics, vol. 155, (Sep., 1982), pp. 342-346.
Ecanow Bernard
Ecanow Charles S.
Neomed Inc.
Rosen Sam
LandOfFree
Synthetic whole blood and a method of making the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic whole blood and a method of making the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic whole blood and a method of making the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2431716